Mouse Model of Alzheimer’s Disease Gets UC San Diego License

Mouse Model of Alzheimer’s Disease Gets UC San Diego License
Tarrytown, New York-based PsychoGenics has announced its Line-41 mouse model of Alzheimer’s disease (AD) has obtained a license from the University of California, San Diego. This experimental model expresses human APP with the London (V717I) and Swedish (K670N/M671L) mutations under the murine-Thy-1 promoter control. PsychoGenics is a leader in providing preclinical central nervous system services. The company has pioneered the translation of rodent behavioral responses into robust, high content phenotyping, and its drug discovery platforms -- PhenoCube, NeuroCube  and SmartCube -- have led to shared-risk partnerships with leading pharmaceutical companies like Roche and Sunovion, resulting in the discovery of several novel compounds, now in clinical trials and advanced preclinical development. In this new model, mice show early onset and progressive plaque disposition in their cerebral cortex and hippocampus as early as three to four months. A number of other hallmarks of human Alzheimer’s disease summarized in the Line-41 mice include:
  • Dystrophic neurites that contain hyperphosphorylated tau protein in the microenvironment of mature plaques and cognitive impairment linked to the appearance of neuro-inflammation, characterized by increased micro-glia activation and astroglioses starting at six months, with a progressive worsening as the amyloid load increases.
The Line-41 mouse model was developed by Profs. Edward Rockenstein
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *